Recently, J.E. Hirsch published a new index to measure an individuals's scientific output, called the h-index. Reference: Hirsch J.E. (2005). An index to quantify an individual's scientific research output. Proc. Natl. Acad. Sci. USA 102: 16569-16572.

Definition: A scientist has index h if h of his/her Np papers have at least h citations each, and the other (Np - h) papers have no more than h citations each.

We can also define m as h divided by the length of a person's scientific career, assuming a simple linear model.

Hirsch writes "From inspection of the citation records of many physicists I conclude:
(1) A value m ~ 1, an h-index of 20 after 20 years of scientific activity, characterizes a successful scientist.
(2) A value m ~2, an h-index of 40 after 20 years of scientific activity, characterizes outstanding scientists, likely to be found only at the top universities or major research laboratories.
(3) A value m ~ 3 or higher, i.e. an h-index of 60 after 20 years, or 90 after 30 years, characterizes truly unique individuals."

For reference, in physics Edward Witten ahs the highest h-index (110). In biology the h-indices seem to be higher, with an h-index for Solomon Snyder of 190, for David Baltimore 160, Bert Vogelstein 151. For new inductees in the NAS USA in the biological and biomedical sciences the average h-index was 57.

In November 2005 my h-index was 22, and I started research in 1982, with a 13 months hiatus along the way for mandatory military service in the Belgian army. Thus, by Hirsch's criteria I am a "successful scientist".

Here are the h-indices for a few other University of Washington, School of Medicine researchers (Dec 2005): Edwin Krebs 103 (Nobel laureate), Roger Palmiter 115, William Catterall 102, Earl Davie 75, Seymour Klebanoff 73, Eugene Nester 68, Bertil Hille 64, Wim Hol 60, Joseph Beavo 56, Steve Hauschka 47, Rachel Klevit 34, Ronald Stenkamp 34, Ethan Merritt 21.

Note: Anyone with access to ISI's Web of Science can look up an individual's h-index in seconds. Look up a person's citations and sort them by number of citations. Apply the h-index definition.

1.	Verlinde C.L., De Ranter C.J. (1983). (1S,5R,9R)-2-cyclopropylmethyl-2'-hydroxy-5,9-dimethyl- 8-oxo-6,7-benzomorphan Hydrochloride Monohydrate (Ketazocine). Acta Cryst. C39, 1703-1706.

2.	Verlinde C.L., Blaton N.M., De Ranter C.J., Peeters O.M. (1984). 5-ethyl-2'-hydroxy-2-[(1-hydroxy-cyclopropyl)-methyl)]- 9,9-dimethyl-6,7-benzomorphan Hydrochloride (Bremazocine). Acta Cryst. C40, 1759-1761.
3.	De Ranter C.J., Verlinde C.L., Blaton N.M., Peeters O.M. (1984). The kappa-active oxygen in the opioid pharmacophore of some benzomorphans: charges, proton affinities and binding modelling. Neuropeptides5, 209-212. [PMID: 6099499]

4.	De Ranter C.J., Verlinde C.L., Blaton N.M., Peeters O.M. (1985). The role of oxygen in the opioid kappa- pharmacophore of some benzomorphans. Arch. Int. Physiol. Biochem. 93, BP6.

5.	Verlinde C.L., De Ranter C.J. (1988). Assessment of the kappa-opioid activity of a series of 6,7-benzomorphans in the rabbit vas deferens. Eur. J. Pharmacol. 153, 83-87. [PMID: 2850928]
6.	Blaton N.M., Vynckier S.M., Verlinde C.L., Peeters O.M., De Ranter C.J. (1988). Structure of 8-chloro-2-[(3-furoyl)-amino- methyl]-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine Hydrochloride. Acta Cryst. C44, 1125-1127.
7.	Verlinde C.L., Blaton N.M., Peeters O.M., De Ranter C.J. (1988). (-)-(1R,5R,9R)-2'-hydroxy-2-(3-methoxypropyl)-5,9- dimethyl-6,7-benzomorphan Hydrobromide Monohydrate. Acta Cryst. C44, 1609-1611.
8.	Verlinde C.L., Blaton N.M., Peeters O.M., De Ranter C.J. (1988). (-)-(1R,5R,9R,2''R)-2'-hydroxy-5,9-dimethyl-2-[(tetrahydro- 2-furyl)ethyl]-6,7-benzomorphan Hydrobromide. Acta Cryst. C44, 1611-1614.
9.	Verlinde C.L., Blaton N.M., Peeters O.M., De Ranter C.J. (1988). (-)-(1R,5R,9R)-2-ethoxyethyl-2'-hydroxy-5,9-dimethyl- 6,7-benzomorphan Hydrobromide. Acta Cryst. C44, 1789-1791.
10.	Verlinde CL., Blaton N.M., Peeters O.M., De Ranter C.J. (1988). (-)-(1R,5R,9R)-2'-hydroxy-2-methoxyethyl-5,9-dimethyl- 6,7-benzomorphan Hydrobromide Monohydrate. Acta Cryst. C44, 1792-1794.

11.	Vanquickenborne L.G., Coussens B., Verlinde C., De Ranter C. (1989). Ab initio analysis of 2-aminoethanol conformers, including electron correlation corrections for the energy. J. Mol. Struct. (Theochem.) 201, 1-15.
12.	Verlinde C.L., De Ranter C.J., Blaton N.M., Peeters O.M. (1989). Static disorder in (-)-(1R,5R,9R,13S)-2'-hydroxy-5,9- dimethyl-2-(2-methyl-tetrahydrofuryl)-6,7-benzomorphan: Crystal structure and MM2 pucker analysis of the tetrahydrofuran ring. Acta Cryst. B45, 107-112.
13.	Verlinde C.L., De Ranter C.J. (1989). Furan revisited: When to avoid ab initio studies on crystal structures. J. Mol. Struct. (Theochem.)187, 161-167.
14.	Verlinde C.L., Blaton N.M., De Ranter C.J., Peeters O.M. (1989). Structure of a kappa-opioid receptor misfit: (1S,5R,8R,9R)-2'- hydroxy-5,9-dimethyl-8,2-epoxyethano-6,7-benzomorphan Hydrochloride. Acta Cryst. C45, 799-803. [PMID: 2557866]
15.	Verlinde C.L., Blaton N.M., Peeters O.M., De Ranter C.J. (1989). Structure and conformational analysis of the opioid antagonist (-)-(1R,5R,9R)-5,9-diethyl-2-(3-furylmethyl)-2'-hydroxy-6,7-benzomor- phan (Mr2266). Acta Cryst. C45, 1797-1802. [PMID: 2610966]
16.	Peeters O.M., Verlinde C.L., Blaton N.M., De Ranter C.J.(1989). Crystal structure and absolute configuration of two stereoisomers of alpha,alpha'-(iminobis(methylene))-bis-(3,4-dihydro-2H-1- benzopyran-2-methanol) Hydrobromide. Acta Cryst. C45, 1930-1933. [PMID: 2576841]

17.	De Ranter C.J., Verlinde C.L. Kappa-opioids in a Series of 6,7-Benzomorphans. Conformational Analysis and Pharmacophore Modelling, in: Frontiers in Drug Research,Alfred Benzon Symposium 28, eds. Jensen B., Jorgensen,F.S. & Kofod H., Munksgaard, Copenhagen, 1990, 30-44.
18.	De Winter H.L., Verlinde C.L., Blaton N.M., Peeters O.M., De Ranter C.J. (1990). Structure of the neuroleptic drug 4-amino-N-1-[(1-ethyl-2-pyrollidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy- benzamide (Amisulpride). Acta Cryst. C46, 313-317. [PMID: 1970258]
19.	Verlinde C.L., Peeters O.M., Blaton N.M., De Ranter C.J. (1990). Structure of the opioid kappa-agonist (-)-(1R,5R,9R,2"S)-2'-hydroxy-2- (2-methoxypropyl)-5,9-dimethyl-6,7-benzomorphan Hydrobromide (I) and its inactive (-)-(1R,5R,9R,2"R) diastereomer (II). Acta Cryst. C46, 663-666.
20.	Vellieux F.M.D., Wierenga R.K., Groendijk H., Read R.J., Noble M.E.M., Verlinde C.L.M.J., Hol W.G.J. (1990). Protein crystallography and the design of new drugs against sleeping sickness. In "Chemotherapy for Trypanosomiasis", Ed. Peregrine A.S., Nairobi, pp. 63-69.

21.	Verlinde C.L.M.J, Noble M.E.M., Kalk K.H., Groendijk H., Wierenga R.K., Hol W.G.J. (1991). Anion binding at the active site of trypanosomal triosephosphate isomerase: Monohydrogen phosphate does not mimic sulphate. Eur. J. Biochem. 198, 53-57. [PMID: 2040290]
22.	Noble M.E.M., Verlinde C.L.M.J., Groendijk H., Kalk K.H., Wierenga R.K., Hol W.G.J.(1991). Crystallographic and molecular modelling studies on trypanosomal triosephosphate isomerase: A critical assessment of the predicted and observed structures of the complex with 2-phosphoglycerate. J. Med. Chem. 34, 2709-2718. [PMID: 1895291]
23.	Verlinde C.L.M.J., Rudenko G., Hol W.G.J. (1991). In search of new lead compounds for trypanosomiasis drug design: A protein structure-based linked-fragment approach. J. Comput.-Aided Mol. Design 6, 131-147. [PMID: 1624956]
24.	Hol W.G.J., Vellieux F.M.D., Verlinde C.L.M.J., Wierenga R.K., Noble M.E.M., Read R.J. Crystallographic investigations of glycolytic enzymes from Trypanosoma brucei: potential starting points for the design of new sleeping sickness drugs. In "Molecular conformation and biological interactions", Eds. Balaram P. & Ramaseshan, Indian Academy of Sciences, Bangalore, 1991, pp. 215-244.

25.

Sander C., Vriend G., Bazan F., Horovitz A., Nakamura H., Ribas L., Finkelstein A.V., Lockhart A., Merkl M., Perry J., Emery S.C., Gaboriaud C., Marks C., Moult J., Verlinde C.L.M.J., Eberhard M., Elofsson A., Hubbard T.J.P., Regan L., Banks J., Jappelli R., Lesk A.M., Tramontano A. (1992). Protein design on computers. Five new proteins: Shpilka, Grendel, Fingerclasp, Leather, and Aida. Proteins: Structure, Function and Genetics12, 105-110.

26.

Verlinde C.L.M.J., Witmans C.J., Pijning T., Kalk K.H., Hol W.G.J., Opperdoes F.R. (1992). Structure of the complex between trypanosomal triosephosphate isomerase and N-hydroxy-4-phosphono- butanamide: Binding at the active site despite an "open" flexible loop conformation. Protein Sci. 1, 1578-1584. [PMID: 1304889]

27.

Vellieux F.M.D., Hajdu J., Verlinde C.L.M.J., Groendijk H., Read R.J., Greenhough T.J., Campbell J.W., Kalk K.H., Littlechild J.A., Watson H.C., Hol W.G.J. (1993). Structure of glycosomal glyceraldehyde-3- phosphate dehydrogenase from Trypanosoma brucei determined from Laue data. Proc. Natl. Acad. Sci. USA 90, 2355-2359. [PMID: 8460146]

28.

Verlinde C.L.M.J., Pijning T, Kalk K.H., van Calenbergh S., Van Aerschot A., Herdewijn P., Callens M., Michels P., Opperdoes F.R., Wierenga R.K., Hol W.G.J. Protein structure-based inhibitor design: towards new drugs for sleeping sickness. In 'Perspectives in Medicinal Chemistry. Proceedings of the XXIIth International Symposium on Medicinal Chemistry', Eds. Testa B., Kyburz E., Fuhrer W. & Giger R., Verlag Helvetica Chimica Acta, Basel, 1993, pp.135-148.

29.	Verlinde C.L.M.J. , Hol W.G.J. (1994). Structure-based drug design: progress, results and challenges. Structure 2, 577-587. [PMID: 7922037] ISI: A 111 citations, and counting ...
30.	Verlinde C.L.M.J., Callens M., Van Calenbergh S., Van Aerschot A., Herdewijn P., Hannaert V., Michels P.A.M., Opperdoes F.R., Hol W.G.J. (1994). Selective inhibition of trypanosomal glyceraldehyde-3- phosphate dehydrogenase by protein structure-based design: Towards new drugs for the treatment of sleeping sickness. J. Med. Chem. 37, 3605-3613. [PMID: 7932587]
31.	Van Calenbergh S., Van Den Eeckhout E., Herdewijn P., De Bruyn A., Verlinde C., Hol W., Callens M., Van Aerschot A., Rozenski J. (1994). Synthesis and conformational analysis of 2'-deoxy-2'- (3-methoxy- benzamido)adenosine, a rationally designed inhibitor of trypanosomal glyceraldehyde phosphate dehydrogenase. Helv. Chim. Acta 77, 631-644.
32.	Verlinde C.L.M.J. , Merritt E.A., van den Akker F., Kim H., Feil I., Delboni L.F., Mande S.C., Sarfaty S., Petra P.H., Hol W.G.J. (1994). Protein crystallography and infectious diseases. Protein Sci. 3, 1670-1686. [PMID: 7849584]

33.	Qiu X., Verlinde C.L.M.J. , Zhang S., Schmitt M.P.,Holmes R.K., Hol W.G.J. (1995). Three-dimensional structure of the diphtheria toxin repressor in complex with divalent cation co-repressors. Structure3, 87-100. [PMID: 7743135]
34.	Kim H., Feil I.K., Verlinde C.L.M.J., Petra P.H., Hol W.G.J. (1995). Crystal structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase: from Leishmania mexicana: Implications for structure- based drug design and a new position for the inorganic phosphate binding site. Biochemistry34, 14975-14986. [PMID: 7578111]
35.	Verlinde C.L.M.J., Dijkstra B.W. (1995). Drug or tool, design or serendipity? Nature Struct. Biol. 2, 429-432. [PMID: 7664101]
36.	Van Calenbergh S.,Verlinde C.L.M.J., Soenens J., De Bruyn A., Callens M., Blaton N.M., Peeters O.M., Hol W.G.J., Herdewijn P. (1995). Synthesis and structure-activity relationships of analogs of 2'-deoxy- 2'-(3-methoxy-benzamido)adenosine, a selective inhibitor of trypanosomal glyceraldehyde phosphate dehydrogenase. J. Med. Chem. 38, 3838-3849. [PMID : 7562915]

37.	Buckner F.S., Verlinde C.L.M.J., La Flamme A.C. & Van Voorhis W.C. (1996). Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob. Agents Chemother. 40, 2592-2597. [PMID: 8913471]

38.	Verlinde C.L.M.J., Kim H., Bernstein B.E., Mande S.C., Hol W.G.J. (1997). Anti-trypanosomiasis drug development based on structures of glycolytic enzymes. In 'Structure-based drug design', Ed. Veerapandian. Marcel Dekker, NY, pp. 365-394.
39.	Verlinde C.L.M.J., Kim H., Bernstein B.E., van den Akker F., Minke W.E., Hovey B., Feil I.K., Sarfaty S., Roach C., Merritt E.A., Hol W.G.J. (1997). Protein crystallography, tropical diseases and drug design. In 'Rational Molecular Design in Drug Research - Alfred Benzon Symposium 42', Eds: Liljefors T., Jorgensen F.S., Krogsgaard-Larsen P. Munksgaard, Copenhagen, pp. 295-305.

40.	Hol W.G.J., van den Akker F., Minke W., Hovey B., Feil I.K., Roach C., Sarafaty S.,Verlinde C.L.M.J., Merritt E.A. (1998). Towards the design of drugs and vaccines on the basis of the three-dimensional structure of cholera toxin and E.coli heat-labile enterotoxin. In 'Bacterial Protein Toxins', Zent. Bl. Bakteriol., Suppl. 29, Eds: Hacker et al., Gustav Fisher, Jena, Stuttgart, Lubeck, Ulm, pp. 17-23.
41.	Aronov A.M., Verlinde C.L.M.J., Hol W.G.J., Gelb M.H. (1998). Selective new inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design. J. Med. Chem. 41, 4790-4799. [PMID: 9822549]
42.	Verlinde C.L.M.J. (1998). Five Orders of Magnitude Affinity Gain in Anti-trypanosomal Drug Development. On-line Proceedings of the 5th Internet World Congress on Biomedical Sciences '98 at McMaster University, Canada [URL: www.mcmaster.ca/inabis98/harmtox/verlinde0900]

43.	Hovey B., Verlinde C.L.M.J., Merritt E.A., Hol W.G.J. (1999). Structure-based discovery of a pore- binding ligand: towards assembly inhibitors for cholera and related AB5 toxins. J. Mol. Biol.285, 1168-1178. [PMID: 9887271]
44.	Palczewski K., Verlinde C.L.M.J., Haeseleer F. (1999). Molecular mechanism of visual transduction. In 'Rhodopsins and photo-transduction' Novartis Foundation Symposium 224, Ed. Bock G., John Wiley & Sons, Chichester, pp. 191-207. [PMID: 10614052]
45.	Aronov A.M., Buckner F.S., Van Voorhis W.C., Verlinde C.L.M.J., Opperdoes F.R., Hol W.G.J., Gelb M.H. (1999). Structure-based design of sub-micromolar, biologically active inhibitors of trypanosomatid glyceraldehyde- 3-phosphate dehydrogenase. Proc. Natl. Acad. Sci. USA 96, 4273-4278. [PMID: 10200252]
46.	Verlinde C.L.M.J., Quigley P.M. (1999). Structure-based reevaluation of the mechanism of class I fructose-1,6-bisphosphate aldolase. J. Mol. Mod. 5, 37-45. [SPRINGER VERLAG: Abstract]
47.	Minke W.E., Roach C., Hol W.G.J., Verlinde C.L.M.J. (1999). Structure-based exploration of the ganglioside GM1 binding sites of E.coli heat-labile enterotoxin and cholera toxin for the discovery of receptor antagonists. Biochemistry 38, 5684-5692. [PMID: 10231518]
48.	Minke W.E., Diller D.J., Hol W.G.J., Verlinde C.L.M.J. (1999). The role of waters in docking strategies with incremental flexibility for carbohydrate derivatives: heat-labile enterotoxin, a multivalent test case. J.Med.Chem. 42, 1778-1788. [PMID : 10346930]
49.	Sokal I., Otto-Bruc A., Surgucheva I., Verlinde C.L.M.J., Wang C.K., Baehr W., Palczewski K. (1999). Conformational changes in guanylyl cyclase-activating protein 1 (GCAP) and its tryptophan mutants as a function of calcium concentration. J. Biol. Chem. 274, 19829-19837. [PMID: 10391927]
50.	Minke W.E., Hong F., Verlinde C.L.M.J., Hol W.G.J., Fan E. (1999). Using a galactose library for exploration of a novel hydrophobic pocket in the receptor binding site of the E. coli heat-labile enterotoxin. J. Biol. Chem. 274, 33469-33473.[PMID: 10559230]
51.	Diller D.J., Verlinde, C.L..M.J. (1999). A critical evaluation of several global optimization algorithms for the purpose of molecular docking. J. Comp. Chem. 20, 1740-1751.
52.	Michels P.A.M., Verlinde C.L.M.J. (1999). Glycolytic enzymes. In "Embryonic Encyclopedia of Life Sciences", Nature Publishing Group., London. [URL: www.els.net]

53.	Haeseleer F., Sokal I., Verlinde C.L.M.J., Erdjument-Bromage H., Tempst P., Pronin A.N., Benovic J.L., Fariss R.N., Palczewski K. (2000). Five members of a novel Ca(2+)-binding protein (CABP) subfamily with similarity to calmodulin. J. Biol. Chem. 275, 1247-1260. [PMID: 10625670]
54.	Fan E., Zhang Z., Minke W.E., Hou Z., Verlinde C.L.M.J.,Hol W.G.J. (2000). High affinity pentavalent ligands of E.coli heat-labile enterotoxin by modular structure-based design. J. Am. Chem. Soc.122, 2663-2664.
55.	Minke W.E., Pickens J., Merritt E.A., Fan E., Verlinde C.L.M.J.,Hol W.G.J. (2000). Crystal structure of m-carboxyphenyl--D-galactose complexed to heat-labile enterotoxin at 1.3 A resolution: surprising variation in ligand binding modes. Acta Crystallogr. D56, 795-804. [PMID: 10930826 ]
56.	Bressi J.C., Choe J., Hough M.T., Buckner F.S., Van Voorhis W.C., Verlinde C.L.M.J., Hol W.G.J., Gelb M.H. (2000). Adenosine analogs as inhibitors of glycolytic enzymes of Trypanosoma brucei with the elucidation of a novel binding mode for a 2-amino-N6-substituted adenosine derivative to phosphoglycerate kinase. J. Med. Chem. 43, 4135-4150. [PMID: 11063610].
57.	Sokal I., Li N., Verlinde C.L.M.J., Haeseleer F., Baehr B., Palczewski K. (2000). Ca2+-Binding proteins in the retina: From discovery to etiology of human disease. Biochim. Biophys. Acta 1498, 233-251. [PMID: 11108966]
58.	Fan E., Merritt E.A., Verlinde C.L.M.J., Hol W.G.J. (2000). AB5 toxins: Structures and inhibitor design. Curr. Op. Struct. Biol. 10, 680-686 [PMID: 11114505]
59.	Cideciyan A.V., Haeseleer F., Fariss R.N., Aleman T.S., Jang G.F., Verlinde C.L.M.J, Marmor M.F., Jacobson S.G., Palczewski K. (2000). Rod and cone visual cycle consequences of a null mutation in the 11-cis-retinol dehydrogenase gene in man. Vis. Neurosci. 17, 667-678 [PMID: 11153648].

60.	Verlinde C.L.M.J., Hannaert V. Blonski C., Willson M., Perie J.J., Fothergill-Gilmore L., Opperdoes F.R., Gelb M.H., Hol W.G.J., P.A.M. Michels (2001). Glycolysis as a target for the design of new anti-trypanosome drugs. Drug Resistance Updates 4, 50-65 [PMID: 11512153].
61.	Suresh S., Bressi J.C., Kennedy K.J., Verlinde C.L.M.J., Gelb M.H., Hol W.G.J. (2001). Conformational changes in Leishmania mexicana glyceraldehyde-3-phosphate dehydrogenase induced by designed inhibitors. J. Mol. Biol. 309, 423-435. [PMID: 11371162]
62.	Bressi J.C., Verlinde C.L.M.J., Aronov A.M, Le Shaw M., Shin S.S., Nguyen L.N., Suresh S.,Buckner F.S., Van Voorhis W.C. , Kuntz I.D., Hol W.G.J.,Gelb M.H. (2001). Adenosine Analogues as Selective Inhibitors of Glyceraldehyde-3-phosphate Dehydrogenase of Trypanosomatidae via Structure-Based Drug Design. J. Med. Chem., 2080-2093 [PMID: 11405646].
63.	Hol W.G.J., Verlinde C.L.M.J. (2001). Crystallography and Medicine. In 'International Tables of Crystallography. Vol. F. Crystallography of Biological Macromolecules' , Eds. Rossmann M.G., Arnold E., Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 10-43.

64.	Pickens J.C., Merritt E.A., Ahn M., Verlinde C.L.M.J., Hol W.G.J., Fan E. (2002). Anchor-Based Design of Improved Cholera Toxin and E. coli Heat-Labile Enterotoxin Receptor Binding Antagonists that Display Multiple Binding Modes. Chem Biol. 9, 215-24. [PMID: 11880036 ]
65.	Verlinde C.L.M.J., Bressi J.C., Choe J., Suresh S., Buckner F.S., Van Voorhis W.C., Michels P.A.M., Gelb M.H., Hol W.G.J. (2002). Protein structure-based design of anti-protozoal drugs. J. Braz. Chem. Soc.13, 843-844.
66.	Zhang Z., Merritt E.A., Ahn M., Roach C., Hou Z., Verlinde C.L.M.J., Hol W.G.J., Fan E. (2002). Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin. J. Am. Chem. Soc. 124, 12991-12998 [PMID: 12405825].

67.	Chen D.H., Brkanac Z., Verlinde C.L.M.J., Tan X.J., Bylenok L., Nochlin D., Matsushita M., Lipe H., Wolff J., Fernandez M., Cimino P.J., Bird T.D., Raskind W.H. (2003). Missense Mutations in the Regulatory Domain of PKCgamma: A New Mechanism for Dominant Nonepisodic Cerebellar Ataxia. Am. J. Hum. Gen. 72, 839-849 [PMID: 12644968 ]
68.	Auerbach S.S., Ramsden R., Stoner M.A., Verlinde C.L.M.J., Hassett C., Omiecinski C.J. (2003). Alternatively-spliced isoforms of the human constitutive androstane receptor. Nucleic Acids Res. 31, 3194-3207 [PMID:  12799447].
69.	Hu X., Nguyen K.T., Verlinde C.L.M.J., Hol W.G., Pei D. (2003). Structure-Based Design of a Macrocyclic Inhibitor for Peptide Deformylase. J. Med. Chem. 46, 3771-3774 [PMID:  12930137].
70.	Buckner F.S., Joubert B.M., Boyle, S.M., Eastman R.T., Verlinde C.L.M.J. , Matsuda S.P.T. (2003). Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. Mol. Biochem. Parasitol. 32, 75-81 [PMID:  14599667].
71.	Fan E., O'Neal C.J., Mitchell D.D., Robien M.A., Zhang Z., Pickens J.C., Tan X.J., Korotkov K., Roach C., Krumm B., Verlinde C.L.M.J. , Merritt E.A., Hol W.G.J. Structural Biology and Structure-based Inhibitor Design of Cholera Toxin and Heat-labile Enterotoxin. Int. J. Med. Microbiol. 294, 217-223 [PMID: 15532979].